5000iu Heparin Sodium Injection Witn GMP

• Application: Surgery
• Usage Mode: IV/Sc
• Suitable for: Elderly, Adult
• State: Liquid
• Shape: Injection
• Type: Biological Products
• Model NO.: AMC14085
• Pharmaceutical Technology: Chemical Synthesis
• Documnets: Copp,Ctd,GMP
• OEM: Available
• Transport Package: 5′s/Box
• Specification: 5000iu/2ml
• Trademark: MEDIPHARM/SHINEPHARM
• Origin: China
• HS Code: 3004909099
• Production Capacity: 500000 Boxes/Month

Product Description

 

1.1 Prophylaxis of Deep Vein Thrombosis

Enoxaparin sodium injection, USP is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):

in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.1)].
in patients undergoing hip replacement surgery, during and following hospitalization.
in patients undergoing knee replacement surgery.
in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness.

1.2 Treatment of Acute Deep Vein Thrombosis

Enoxaparin sodium injection, USP is indicated for:

the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium.
the outpatient treatment of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium.

1.3 Prophylaxis of Ischemic Complications of Unstable Angina and Non-Q-Wave Myocardial Infarction

Enoxaparin sodium injection, USP is indicated for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.

1.4 Treatment of Acute ST-Segment Elevation Myocardial Infarction

Enoxaparin sodium injection, USP, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute ST-segment elevation myocardial infarction (STEMI) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (PCI).